{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T07:53:29Z","timestamp":1707465209288},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2014,10,16]],"date-time":"2014-10-16T00:00:00Z","timestamp":1413417600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Bone Miner Metab"],"published-print":{"date-parts":[[2015,9]]},"DOI":"10.1007\/s00774-014-0623-5","type":"journal-article","created":{"date-parts":[[2014,10,15]],"date-time":"2014-10-15T03:11:39Z","timestamp":1413342699000},"page":"584-590","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Clinical efficacy of oral risedronate therapy in Japanese patients with Paget\u2019s disease of bone"],"prefix":"10.1007","volume":"33","author":[{"given":"Masaya","family":"Ohara","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasuo","family":"Imanishi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuki","family":"Nagata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akira","family":"Ishii","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ikue","family":"Kobayashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katsuhito","family":"Mori","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manabu","family":"Ito","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takami","family":"Miki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshiki","family":"Nishizawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masaaki","family":"Inaba","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2014,10,16]]},"reference":[{"key":"623_CR1","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1007\/s00774-005-0670-z","volume":"24","author":"J Hashimoto","year":"2006","unstructured":"Hashimoto J, Ohno I, Nakatsuka K, Yoshimura N, Takata S, Zamma M, Yabe H, Abe S, Terada M, Yoh K, Fukunaga M, Cooper C, Morii H, Yoshikawa H, Japanese Committee on Clinical Guidelines of D, Treatment of Paget\u2019s Disease of Bone of the Japan Osteoporosis S (2006) Prevalence and clinical features of Paget\u2019s disease of bone in Japan. J Bone Miner Metab 24:186\u2013190","journal-title":"J Bone Miner Metab"},{"key":"623_CR2","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1097\/BOR.0b013e32833af61e","volume":"22","author":"A Falchetti","year":"2010","unstructured":"Falchetti A, Masi L, Brandi ML (2010) Paget\u2019s disease of bone: there\u2019s more than the affected skeletal\u2014a clinical review and suggestions for the clinical practice. Curr Opin Rheumatol 22:410\u2013423","journal-title":"Curr Opin Rheumatol"},{"key":"623_CR3","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1016\/j.bone.2003.12.011","volume":"34","author":"JP Walsh","year":"2004","unstructured":"Walsh JP, Ward LC, Stewart GO, Will RK, Criddle RA, Prince RL, Stuckey BG, Dhaliwal SS, Bhagat CI, Retallack RW, Kent GN, Drury PJ, Vasikaran S, Gutteridge DH (2004) A randomized clinical trial comparing oral alendronate and intravenous pamidronate for the treatment of Paget\u2019s disease of bone. Bone 34:747\u2013754","journal-title":"Bone"},{"key":"623_CR4","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1359\/jbmr.061001","volume":"22","author":"D Hosking","year":"2007","unstructured":"Hosking D, Lyles K, Brown JP, Fraser WD, Miller P, Curiel MD, Devogelaer JP, Hooper M, Su G, Zelenakas K, Pak J, Fashola T, Saidi Y, Eriksen EF, Reid IR (2007) Long-term control of bone turnover in Paget\u2019s disease with zoledronic acid and risedronate. J Bone Miner Res 22:142\u2013148","journal-title":"J Bone Miner Res"},{"key":"623_CR5","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1056\/NEJMoa044241","volume":"353","author":"IR Reid","year":"2005","unstructured":"Reid IR, Miller P, Lyles K, Fraser W, Brown JP, Saidi Y, Mesenbrink P, Su G, Pak J, Zelenakas K, Luchi M, Richardson P, Hosking D (2005) Comparison of a single infusion of zoledronic acid with risedronate for Paget\u2019s disease. N Engl J Med 353:898\u2013908","journal-title":"N Engl J Med"},{"key":"623_CR6","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1016\/S0002-9343(99)00062-5","volume":"106","author":"PD Miller","year":"1999","unstructured":"Miller PD, Brown JP, Siris ES, Hoseyni MS, Axelrod DW, Bekker PJ (1999) A randomized, double-blind comparison of risedronate and etidronate in the treatment of Paget\u2019s disease of bone. Paget\u2019s Risedronate\/Etidronate Study Group. Am J Med 106:513\u2013520","journal-title":"Am J Med"},{"key":"623_CR7","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1007\/s00774-009-0152-9","volume":"28","author":"K Yoh","year":"2010","unstructured":"Yoh K, Takata S, Yoshimura N, Hashimoto J (2010) Efficacy, tolerability, and safety of risedronate in Japanese patients with Paget\u2019s disease of bone. J Bone Miner Metab 28:468\u2013476","journal-title":"J Bone Miner Metab"},{"key":"623_CR8","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1007\/s10067-012-2109-y","volume":"32","author":"Y Nishida","year":"2013","unstructured":"Nishida Y, Yamada Y, Tsukushi S, Sugiura H, Urakawa H, Ishiguro N (2013) Midterm outcome of risedronate therapy for patients with Paget\u2019s disease of bone in the central part of Japan. Clin Rheumatol 32:241\u2013245","journal-title":"Clin Rheumatol"},{"issue":"Suppl 2","key":"623_CR9","doi-asserted-by":"crossref","first-page":"P92","DOI":"10.1359\/jbmr.06s217","volume":"21","author":"PL Selby","year":"2006","unstructured":"Selby PL (2006) Guidelines for the diagnosis and management of Paget\u2019s disease: a UK perspective. J Bone Miner Res 21(Suppl 2):P92\u2013P93","journal-title":"J Bone Miner Res"},{"key":"623_CR10","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/j.bone.2004.03.023","volume":"35","author":"IR Reid","year":"2004","unstructured":"Reid IR, Davidson JS, Wattie D, Wu F, Lucas J, Gamble GD, Rutland MD, Cundy T (2004) Comparative responses of bone turnover markers to bisphosphonate therapy in Paget\u2019s disease of bone. Bone 35:224\u2013230","journal-title":"Bone"},{"key":"623_CR11","doi-asserted-by":"crossref","first-page":"1592","DOI":"10.1093\/clinchem\/41.11.1592","volume":"41","author":"A Blumsohn","year":"1995","unstructured":"Blumsohn A, Naylor KE, Assiri AM, Eastell R (1995) Different responses of biochemical markers of bone resorption to bisphosphonate therapy in Paget disease. Clin Chem 41:1592\u20131598","journal-title":"Clin Chem"},{"key":"623_CR12","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1093\/clinchem\/46.5.684","volume":"46","author":"HW Woitge","year":"2000","unstructured":"Woitge HW, Oberwittler H, Heichel S, Grauer A, Ziegler R, Seibel MJ (2000) Short- and long-term effects of ibandronate treatment on bone turnover in Paget disease of bone. Clin Chem 46:684\u2013690","journal-title":"Clin Chem"},{"key":"623_CR13","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1016\/S8756-3282(02)00817-7","volume":"31","author":"PL Selby","year":"2002","unstructured":"Selby PL, Davie MW, Ralston SH, Stone MD, Bone, Tooth Society of Great B, National Association for the Relief of Paget\u2019s D (2002) Guidelines on the management of Paget\u2019s disease of bone. Bone 31:366\u2013373","journal-title":"Bone"},{"key":"623_CR14","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1038\/nrrheum.2009.149","volume":"5","author":"FR Singer","year":"2009","unstructured":"Singer FR (2009) Paget disease: when to treat and when not to treat. Nat Rev Rheumatol 5:483\u2013489","journal-title":"Nat Rev Rheumatol"},{"key":"623_CR15","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1093\/rheumatology\/keh185","volume":"43","author":"L Alvarez","year":"2004","unstructured":"Alvarez L, Peris P, Guanabens N, Vidal S, Quinto L, Monegal A, Pons F, Ballesta AM, Munoz-Gomez J (2004) Long-term biochemical response after bisphosphonate therapy in Paget\u2019s disease of bone. Proposed intervals for monitoring treatment. Rheumatology (Oxford) 43:869\u2013874","journal-title":"Rheumatology (Oxford)"},{"key":"623_CR16","first-page":"3993","volume":"81","author":"SE Papapoulos","year":"1996","unstructured":"Papapoulos SE, Frolich M (1996) Prediction of the outcome of treatment of Paget\u2019s disease of bone with bisphosphonates from short-term changes in the rate of bone resorption. J Clin Endocrinol Metab 81:3993\u20133997","journal-title":"J Clin Endocrinol Metab"},{"key":"623_CR17","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1002\/jbmr.5650110817","volume":"11","author":"AG Randall","year":"1996","unstructured":"Randall AG, Kent GN, Garcia-Webb P, Bhagat CI, Pearce DJ, Gutteridge DH, Prince RL, Stewart G, Stuckey B, Will RK, Retallack RW, Price RI, Ward L (1996) Comparison of biochemical markers of bone turnover in Paget disease treated with pamidronate and a proposed model for the relationships between measurements of the different forms of pyridinoline cross-links. J Bone Miner Res 11:1176\u20131184","journal-title":"J Bone Miner Res"},{"key":"623_CR18","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1359\/JBMR.041212","volume":"20","author":"P Alexandersen","year":"2005","unstructured":"Alexandersen P, Peris P, Guanabens N, Byrjalsen I, Alvarez L, Solberg H, Cloos PA (2005) Non-isomerized C-telopeptide fragments are highly sensitive markers for monitoring disease activity and treatment efficacy in Paget\u2019s disease of bone. J Bone Miner Res 20:588\u2013595","journal-title":"J Bone Miner Res"},{"key":"623_CR19","first-page":"502","volume":"22","author":"E Cacace","year":"2004","unstructured":"Cacace E, Ruggiero V, Matulli C, Uras L, Perpignano G (2004) Markers of bone resorption in bisphosphonate therapy of Paget\u2019s disease. Clin Exp Rheumatol 22:502","journal-title":"Clin Exp Rheumatol"},{"key":"623_CR20","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1007\/s00774-006-0696-x","volume":"24","author":"S Takata","year":"2006","unstructured":"Takata S, Hashimoto J, Nakatsuka K, Yoshimura N, Yoh K, Ohno I, Yabe H, Abe S, Fukunaga M, Terada M, Zamma M, Ralston SH, Morii H, Yoshikawa H (2006) Guidelines for diagnosis and management of Paget\u2019s disease of bone in Japan. J Bone Miner Metab 24:359\u2013367","journal-title":"J Bone Miner Metab"},{"key":"623_CR21","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1002\/jbmr.5650081209","volume":"8","author":"S Patel","year":"1993","unstructured":"Patel S, Stone MD, Coupland C, Hosking DJ (1993) Determinants of remission of Paget\u2019s disease of bone. J Bone Miner Res 8:1467\u20131473","journal-title":"J Bone Miner Res"},{"key":"623_CR22","doi-asserted-by":"crossref","first-page":"2321","DOI":"10.1002\/art.11136","volume":"48","author":"F Joshua","year":"2003","unstructured":"Joshua F, Epstein M, Major G (2003) Bisphosphonate resistance in Paget\u2019s disease of bone. Arthritis Rheum 48:2321\u20132323","journal-title":"Arthritis Rheum"},{"issue":"Suppl 2","key":"623_CR23","doi-asserted-by":"crossref","first-page":"P88","DOI":"10.1359\/jbmr.06s216","volume":"21","author":"SE Papapoulos","year":"2006","unstructured":"Papapoulos SE, Eekhoff EM, Zwinderman AH (2006) Acquired resistance to bisphosphonates in Paget\u2019s disease of bone. J Bone Miner Res 21(Suppl 2):P88\u2013P91","journal-title":"J Bone Miner Res"},{"key":"623_CR24","first-page":"133","volume":"58","author":"HI Harinck","year":"1986","unstructured":"Harinck HI, Bijvoet OL, Vellenga CJ, Blanksma HJ, Frijlink WB (1986) Relation between signs and symptoms in Paget\u2019s disease of bone. Q J Med 58:133\u2013151","journal-title":"Q J Med"},{"key":"623_CR25","doi-asserted-by":"crossref","unstructured":"Meunier PJ, Salson C, Mathieu L, Chapuy MC, Delmas P, Alexandre C, Charhon S (1987) Skeletal distribution and biochemical parameters of Paget\u2019s disease. Clin Orthop Relat Res 217:37\u201344","DOI":"10.1097\/00003086-198704000-00006"},{"key":"623_CR26","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1002\/art.1780400312","volume":"40","author":"L Alvarez","year":"1997","unstructured":"Alvarez L, Peris P, Pons F, Guanabens N, Herranz R, Monegal A, Bedini JL, Deulofeu R, Martinez de Osaba MJ, Munoz-Gomez J, Ballesta AM (1997) Relationship between biochemical markers of bone turnover and bone scintigraphic indices in assessment of Paget\u2019s disease activity. Arthritis Rheum 40:461\u2013468","journal-title":"Arthritis Rheum"},{"key":"623_CR27","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1007\/s00223-005-0247-9","volume":"79","author":"P Peris","year":"2006","unstructured":"Peris P, Alvarez L, Vidal S, Kasper D, Leeming DJ, Monegal A, Angeles Martinez M, Pons F, Guanabens N (2006) Biochemical response to bisphosphonate therapy in pagetic patients with skull involvement. Calcif Tissue Int 79:22\u201326","journal-title":"Calcif Tissue Int"},{"key":"623_CR28","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1007\/s00198-009-0838-9","volume":"20","author":"R Civitelli","year":"2009","unstructured":"Civitelli R, Armamento-Villareal R, Napoli N (2009) Bone turnover markers: understanding their value in clinical trials and clinical practice. Osteoporos Int 20:843\u2013851","journal-title":"Osteoporos Int"},{"key":"623_CR29","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1016\/j.bone.2010.12.006","volume":"48","author":"M Tsujimoto","year":"2011","unstructured":"Tsujimoto M, Chen P, Miyauchi A, Sowa H, Krege JH (2011) PINP as an aid for monitoring patients treated with teriparatide. Bone 48:798\u2013803","journal-title":"Bone"},{"key":"623_CR30","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1007\/s00223-012-9599-0","volume":"91","author":"SH Ralston","year":"2012","unstructured":"Ralston SH, Layfield R (2012) Pathogenesis of Paget disease of bone. Calcif Tissue Int 91:97\u2013113","journal-title":"Calcif Tissue Int"}],"container-title":["Journal of Bone and Mineral Metabolism"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00774-014-0623-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00774-014-0623-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00774-014-0623-5","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,19]],"date-time":"2022-04-19T23:55:52Z","timestamp":1650412552000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00774-014-0623-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,10,16]]},"references-count":30,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2015,9]]}},"alternative-id":["623"],"URL":"https:\/\/doi.org\/10.1007\/s00774-014-0623-5","relation":{},"ISSN":["0914-8779","1435-5604"],"issn-type":[{"value":"0914-8779","type":"print"},{"value":"1435-5604","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,10,16]]}}}